United States: Education

Companies must understand where product components are sourced from, and where all steps of the manufacturing process occur. Failure to do so could result in meaningful regulatory and litigation risk.

On July 1, 2025, the California attorney general (AG) announced a $1.55 million settlement (pending court approval) with Healthline Media, LLC (Healthline), who publishes Healthline.com...

Our notable ruling roundup aims to keep our readers up to date on recent rulings in the food & consumer packaged goods space.

The New Jersey Division of Consumer Affairs has issued proposed regulations to further detail and implement the New Jersey Data Privacy Act (NJDPA)—the state's comprehensive...

In this episode of "Clearly Conspicuous," consumer protection attorney Anthony DiResta provides an early analysis of the Federal Trade Commission's (FTC) direction under Chair Andrew Ferguson...

One week remains for clients to submit comments in response to review of potential reciprocal tariffs being conducted by the U.S. Trade Representative ("USTR").

POM Wonderful v FTC - Both Sides Claim Victory even though the Court says: "neither side’s position as to the claims made or adequacy of substantiation has been totally vindicated."

On May 30, 2012, the public comment period began for proposed regulations issued by thirteen New York State agencies (including the Department of Health, the Office of Mental Health, and the Office of Children and Family Services) seeking to limit the executive compensation paid by, and administrative costs of, service providers that receive State funding.

On May 21, 2012, the Ninth Circuit Court of Appeals held that because the use of medical marijuana remains illegal under federal law, the Americans with Disabilities Act (ADA) does not protect against discrimination on the basis of medical marijuana use, even if that use is in accordance with state law explicitly authorizing such use.

As reported in the Citizen Times, North Carolina's nicotine vaping product registry became fully active on July 1, 2025.

Congress and FDA lauded the Modernization of Cosmetics Regulation Act (MoCRA), enacted in 2022, as sweeping federal legislation to increase cosmetic safety and quality standards.

The Supreme Court of Appeals of West Virginia declined to decide whether West Virginia allows for public nuisance claims against distributors of prescription opioids.